2022
DOI: 10.1007/s11547-022-01508-2
|View full text |Cite
|
Sign up to set email alerts
|

A comparative analysis of thermal ablation techniques in the treatment of primary and secondary lung tumors: a single-center experience

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
6
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 30 publications
0
6
0
Order By: Relevance
“…A meta-analysis has confirmed that there is no significant difference in the incidence of pneumothorax between RFA and MWA in the treatment of CRLM 30 . Additionally, a recent comparative study has also yielded similar results 6 . Ablation type was not included in the final model generated in this study; however, it did have an impact on the marginal effect of the number of tumour ablations on pneumothorax.…”
Section: Discussionmentioning
confidence: 56%
See 1 more Smart Citation
“…A meta-analysis has confirmed that there is no significant difference in the incidence of pneumothorax between RFA and MWA in the treatment of CRLM 30 . Additionally, a recent comparative study has also yielded similar results 6 . Ablation type was not included in the final model generated in this study; however, it did have an impact on the marginal effect of the number of tumour ablations on pneumothorax.…”
Section: Discussionmentioning
confidence: 56%
“…The 3-year OS rate achieved by IGTA in the treatment of CRLM within 3 cm size reached an impressive 84% 3 , positioning it as a viable alternative to pneumoresection 4 , 5 . While IGTA is generally considered safe and reproducible, with minor damage to lung structure and reserve function, the presence of associated complications, especially pneumothorax, poses a significant limitation to the technique 6 .…”
Section: Introductionmentioning
confidence: 99%
“…A wide range of therapeutic options has been developed for treatment of primary and secondary liver tumors to compensate for the limited effectiveness of systemic therapies [54][55][56][57][58][59][60][61][62][63][64][65].…”
Section: Discussionmentioning
confidence: 99%
“…Treatment options for LM may include local therapies, such as thermal ablation techniques and stereotactic ablative body radiation [ 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 ], chemotherapy [ 97 , 98 ] and, in selected cases, surgery [ 99 , 100 , 101 ]. The introduction of new systemic treatments, including immunotherapy and target therapies, has improved the prognosis of patients with metastatic tumors, but only a subset of mutated patients can benefit from such treatments [ 102 ].…”
Section: Discussionmentioning
confidence: 99%